The aim of this study was to determine histologic findings in the maxilaarysinus mucosa by scanning electron microscopy (SEM) and transmission electron microscopy (TEM), and ciliary activity within the nasal cavity by measuring the speed of mucociliary transport and after endoscopic sinus surgery (ESS). Thirty patients were enrolled. Thirty-eight antral mucosae of 24 24 patients were investigated according to ultrastructural changes and 6 patients were accepted as controls. At the 12th week, 12 antral nasal mucosae specimens of 8 patients were evaluated. All the specimens were taken from the medial rear wall of the antrum. The specimens were observed under a SEM and TEM. The mucociliary activity was measured within the nasal cavity by a saccharin test in all patients before the operation and after 12 weeks. Twenty people served as controls. In the specimens of the preoperative mucosa, the ciliated epithelium was heavily deciliated, interdigitation of the cell was loosened. In the samples taken 12 weeks after the operation, the ciliated cells were irregularly seen, the number of goblet cells was about the same as in the preoperative group and in the control, the number of the gland openings was higher than in the preoperative group and in the control. Also the interdigitation of the cells was enhanced. The histological and morphological features of the mucosa had improved. The period of the preoperative saccharin test was 12.15 minutes, whereas the period of the postoperative test was 9.08 minutes. The improvement was significant but both results were also significantly longer compared to the controls. These observations suggest that the histological, morphological and mucocilliary activity of the mucosa have not yet improved completely, it takes more than 12 weeks to recover, and the patients should be closely monitored in the postoperative months.
Download full-text PDF |
Source |
---|
Acute necrotizing otitis media is a severe middle ear infection which causes necrosis of the tympanic cavity. A 54-year-old female was presented who suffered from diabetes mellitus and end-stage renal disease presenting with severe otalgia, initially thought to be necrotizing otitis externa. She rapidly progressed to total necrosis of the tympanic membrane.
View Article and Find Full Text PDFInt Forum Allergy Rhinol
January 2025
Department of Otorhinolaryngology, Mayo Clinic in Arizona, Scottsdale, Arizona, USA.
Background/aim: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disease associated with nasal polyposis. Multiple biologics are used for managing EGPA, including some approved for nasal polyps (NP). This study investigated real-world biologic prescription patterns for EGPA and their impact on NP and endoscopic sinus surgery (ESS) use.
View Article and Find Full Text PDFRhinology
January 2025
Kuopio, Finland.
Chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (N-ERD) frequently coexist, forming a complex multimorbid condition often referred to as "global airway disease." This concept reflects shared pathophysiological mechanisms of eosinophilic inflammation and underscores the need for integrated treatment strategies targeting both upper and lower airway manifestations (1). The burden of severe CRSwNP, asthma, and N-ERD is substantial, particularly in terms of reduced quality of life, recurrent exacerbations, revision endoscopic sinus surgeries (ESS), and healthcare utilization (2).
View Article and Find Full Text PDFInt Forum Allergy Rhinol
January 2025
Department of Otorhinolaryngology - Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Am J Otolaryngol
January 2025
Department of Adult and Development Age Human Pathology "Gaetano Barresi", Unit of Otorhinolaryngology, University of Messina, Via Consolare Valeria 1, 98125 3, Italy. Electronic address:
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by a type 2 pattern of inflammation. Mepolizumab was approved for the treatment of CRSwNP in 2021. However, there is a lack of real-life studies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!